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INTRODUCTION
Toca 511 (vocimagene amiretrorepvec) is a novel retroviral replicat-
ing vector (RRV) currently in Phase I clinical trials (NCT01156584 and 
NCT01470794) for the treatment of recurrent high grade (Grade III 
and IV) gliomas (HGG).1 Toca 511 selectively delivers an optimized 
yeast-derived cytosine deaminase transgene (CD) to dividing tumor 
cells. The RRV spreads and integrates proviral DNA copies into the 
genome of infected cells, leading to the expression of the CD enzyme. 
Subsequent administration of the orally bioavailable prodrug 
5- fluorocytosine (5-FC) leads to local conversion of 5-FC to the anti-
cancer drug, 5-fluorouracil (5-FU) in the CD-expressing tumor cells.2,3
The tumor specificity of Toca 511 has been demonstrated in 
rodent models and was originally proposed based on both the 
high specificity of gamma-retroviruses for replicating cells and the 
defects in innate immunity that are known to occur in most tumors.4 
As part of the current dose-escalation safety studies, Toca 511 was 
administered one time either by stereotactic, intratumoral injection 
or by injection into the walls of the surgical resection cavity after 
tumor resection. After waiting several weeks to allow Toca 511 to 
infect neighboring tumor cells, a course of 5-FC (extended-release, 
Toca FC) was taken orally. Since Toca 511 is a nonlytic integrating 
retrovirus and 5-FU kills during cell replication,5,6 infected tumor 
cells not destroyed by the first cycle of Toca FC may continue to 
produce virus and infect residual tumor cells. In the current trials, 
cycles of viral spread by intratumoral replication (for either 3 or 
7 weeks) alternate with 6–8 day courses of Toca FC to evaluate both 
safety and potential efficacy.
Although nonreplicative viral vectors have been investigated pre-
viously as therapeutic agents,7,8 there has been no published study 
of the compatibility or stability of viruses being investigated in the 
treatment of HGG with the equipment or materials used in preclini-
cal and clinical studies. Therefore, for these first-in-human studies, 
it is necessary to understand how routine compounds, hemostatic 
agents, delivery devices, biofluids, and procedures associated with 
a neuro-surgical setting could impact the administration, stability, 
and infectivity of the Toca 511 vector.
We investigated the following areas: (i) post thaw stability of 
Toca 511 and the impact of dwell times with various surgical deliv-
ery devices, (ii) compatibilities with solvents, adjuvants, hemostatic 
agents, and biofluids that may come into contact with Toca 511 
during or after surgery, (iii) biocompatibility of Toca 511 with track-
ing and infectivity enhancing agents, and (iv) the effect on Toca 511 
of solvents frequently used in other agents (ethanol and dimethyl 
 sulfoxide (DMSO)), and adjuvants. This report describes the results of 
this survey and provides guidance for the use of materials in conjunc-
tion with Toca 511 in the OR.
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Toca 511 is a novel retroviral replicating vector, encoding a modified yeast cytosine deaminase, administered to recurrent high 
grade glioma patients in Phase 1 trials by stereotactic, transcranial injection into the tumor or into the walls of the resection cavity. 
A key issue, with little published data, is vector biocompatibility with agents likely to be encountered in a neurosurgical setting. 
We tested biocompatibility of Toca 511 with: delivery devices; MRI contrast agents, including ProHance supporting coinjection for 
real time MRI-guided intratumoral delivery; hemostatic agents; biofluids (blood and cerebrospinal fluid); potential adjuvants; and a 
needleless vial adapter that reduces risk of accidental needle sticks. Toca 511 is stable upon thawing at ambient temperature for at 
least 6 hours, allowing sufficient time for administration, and its viability is not reduced in the presence of: stainless steel and silica-
based delivery devices; the potential MRI contrast agent, Feraheme; ProHance at several concentrations; the hemostatic agent 
SURGIFOAM; blood; cerebrospinal fluid; and the needleless vial adapter. Toca 511 is not compatible with the hemostatic agent 
SURGICEL or with extended exposures to titanium-based biopsy needles.
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ReSUlTS
General format of stability testing experiments
Compatibility assessments were made by incubating Toca 511 
and a delivery device (needle, catheter, or cannula), MRI contrast 
agent, hemostatic agent, biofluid, or other solvents (or combina-
tion thereof), and then determining the resulting transduction titer 
(TU/ml) compared with control test articles. Usually, the compatibil-
ity assessment represents incubations over time periods that may 
occur in a clinical or surgical setting.
The transduction titer assay for Toca 511 depends on the time of 
exposure to target cells and azidothymidine (AZT) at 24 hours 
prevents subsequent spread
Figure 1a (open squares) shows the resulting transduction titers 
on PC-3 cells in 12-well plates and the rate of vector uptake. These 
data show a highest value of 3 × 108 TU/ml after a minimum of 
6-hour exposure, and this value stays steady out to 24 hours. 
Therefore, a 16–24-hour exposure of Toca 511 to PC-3 cells was 
used in subsequent experiments. Because Toca 511 is replication 
competent, AZT is used to inhibit subsequent replication, after 
the first round of infection is complete. The determination of 
transduction titer of Toca 511 was investigated by incubating vec-
tor-transduced host cells with and without the addition of AZT to 
40 µmol/l. Figure 1b shows the titer determinations for untreated 
cells, cells treated once with AZT, and cells with additions every 
24 hours (4 total for 96 hours). Based on these data, the assay was 
performed subsequently using a single AZT administration at 
20–28 hours posttransduction.
Needleless vial adapters allow sterile extraction of material from 
the filled vial and avoids needle sticks
The exterior of the 2 ml glass vial in which Toca 511 is supplied is not 
sterile and could not be handled directly by a surgeon in the oper-
ating room (OR). To extract vector from the vial in the OR, a sterile 
13 mm needless vial adaptor (West Pharmaceutical; Ref # 8070117), 
was aseptically placed by a surgical assistant over the Toca 511 vial, 
snap fitting into place. This allows the surgeon to remove the vec-
tor from the vial using a sterile syringe without having to directly 
contact the vial and break sterility. Volume recovery and compat-
ibility studies indicated a loss of 0.2 ml (from a vial with 0.8 or 1.7 ml 
fill volume) associated with the use of the vial adaptor and no loss 
in transduction titer for the recovered vector. An additional benefit 
of the use of this vial adaptor is the reduced risk of an accidental 
needle stick injury. Over 70 patients have now been treated with 
vector extracted this way without needle sticks or patient infections 
attributable to this system.
Toca 511 is compatible with MRI contrast agents
Mixing MRI contrast agents with Toca 511 is potentially useful for 
verifying catheter placement and tracking in vivo delivery of Toca 
511 in a tumor. Visualization in real time of the delivery of the mix-
ture by MRI allows rapid assessment of alternative delivery devices, 
including convection-enhanced delivery (CED) methods14,15,19,20,22,23 
at different possible flow rates and delivery volumes. To assess the 
utility of such methods, we conducted pilot studies for two poten-
tial MRI contrast strategies: mixing of gadolinium-based small mol-
ecule contrast agents with vector preparations to allow real-time 
Figure 1 Optimization, characterization, and representative stability and compatibility data for the Toca 511 transduction titer assay. (a) Determination 
of appropriate time for transduction. The transduction timing was measured by determining transduction titers for Toca 511 after replacing cell culture 
media of transductant host cells at the indicated times (open squares, an average of three determination/time point). The vector uptake rate (open 
circles, second y-axis) was determined by calculating the total number of proviral copy number (by qPCR) generated with the given transduction 
time intervals. (b) AZT timing to determine single round of transduction. AZT is added to 40 µmol/l 24 hours after transduction (single addition of 
AZT, open squares; multiple addition AZT, open triangles, timing as indicated) to prevent additional replication and spread of Toca 511 (determined 
by measuring titer). (c) Representative transduction titer results of an ambient temperature time-course profile of Toca 511 incubated with ProHance. 
ProHance (Gadoteridol Injection, 279.3 mg/ml) was diluted 1:31, 1:11, and 1:6 in saline (plus 100%, undiluted) followed by incubation at 1:17 with Toca 
511 (0.53 mg/ml, 1.49 mg/ml, 2.74 mg/ml, and 16.43 mg/ml, respectively).
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MRI visualization of vector delivery (Figure 2a) and mixing of iron 
nanoparticles21 with vector to allow real time and sustained tracking 
over several weeks (performed in mice, Figure 2b,c). Further details 
of these experiments will be published elsewhere. In preparation for 
these studies, we performed biocompatibility testing of Toca 511 
with the MRI contrast agents ProHance (Gadoteridol Injection) and 
Feraheme (Ferumoxytol Injection).21
A 1:31 dilution of ProHance saline solution was added to Toca 511 
(at 1:17) and infused at a rate of 1.2 µl/min through a sterile fused 
silica CED catheter (Polymicro Technologies, Phoenix, AZ ) attached 
to PFA Teflon tubing. Results summarized in Table 1 show no loss of 
transduction titers compared with controls over 4 hours at  ambient 
temperature, indicating good compatibility. Additional studies with 
2:31, 1:11, 1:6 (ProHance:saline) solutions and undiluted ProHance 
mixed with Toca 511 also resulted in no loss of titer over a 6 hours 
ambient incubation. The 2:31 sample was infused manually through 
a BrainLAB AG disposable biopsy needle, while collecting samples 
every 2  hours for titer measurement. These results supported 
 incorporation of ProHance into our current clinical protocol; Toca 511 
is combined with a gadoteridol saline solution to a final 0.53 mg/ml 
concentration (1:31, the lowest concentration of gadoteridol 
tested), and this procedure allows real time MRI in vivo visualization 
of Toca 511 placement. A representative coronal T1-weighted MRI 
image obtained from our clinical study using 0.53 mg/ml concentra-
tions of gadoteridol is shown in Figure 2a.
Feraheme compatibility with Toca 511 was investigated in a 
similar assay matrix to ProHance. Mixing Feraheme with an RRV 
can be used to track the delivery of an injectate by either histo-
chemical staining or by MRI detection as shown in Figure 2b,c in 
preclinical mouse model studies. 1:31, 1:11, 1:6, straight dilutions 
of stock Feraheme were prepared as for ProHance in saline and 
combined with Toca 511 at 1:17. Table 1 summarizes the results 
and shows compatibility at up to the highest concentration of 
Feraheme.
Toca 511 is stable over 6 hours without and with ProHance
The titer of Toca 511 was monitored for ambient (18–23 °C) tem-
perature stability over a period 6 hours to allow for delays during 
surgical administration. Figure 1c shows transduction titer results of 
Toca 511 monitored over 6 hours at ambient temperature with or 
without various concentration of the MRI contrast agent ProHance 
(Gadoteridol) upon being passed through a stainless steel biopsy 
needle. Table 1 shows that transduction titers did not change 
beyond 0.108 log of the control condition when incubated with 
ProHance at various concentrations.
Toca 511 is compatible with several delivery devices but not 
titanium needles
Compatibility of Toca 511 was assessed with stainless steel and tita-
nium biopsy needles, a Rickham Catheter/Reservoir (polysulfone) 
and the Medtronic Acute Neurological Therapy Infusion System 
(MANTIS) investigational intracerebral delivery system. The results 
are shown in Table 2 and indicate complete compatibility with all 
Figure 2 In vivo deliveries of retroviral vector with MRI contrast agents ProHance and Feraheme. (a) Toca 511 delivered intracranially with gadoteridol 
injection (0.53 mg/ml) to a human subject with glioblastoma visualized in real time with MRI during administration. (b) Histochemistry of a B6C3F1 
mouse brain stained with Prussian blue after injection with RRV mixed with 15 μg Feraheme showing distribution of Feraheme particles magnified 
in the inset. (c) T2 SWI MRI at 7 Tesla of brain section shown in (b) demonstrating strong Feraheme localization. MRI, magnetic resonance imaging; 
SWI, susceptibility weighted imaging.
a b c
Table 1 Compatibility of Toca 511 with MRI contrast agents
Contrast agent Difference from 
CTRL (log)
Compatibility Notes on methodology  
(all incubations and dwell times occur at ambient temperatures)
ProHance: study A (w/CED catheter; 
Polymicro Technologies)
0.089 +++ 1:31 saline dilution of ProHance mixed with undiluted vector (1:17); Infused 
at a rate of 1.2 µl/min. over 4 hr via laboratory syringe pump.
ProHance: study B (w/Steel Biopsy 
Needle (BrainLAB)
0.108a ++ 2:31 saline dilution of ProHance mixed with undiluted vector (1:17); slow 
manual infusion through the needle and collected at intervals over 6 hours.
ProHance: study Cb 0.065 +++ 1:31, 1:11, 1:6 saline dilutions of ProHance (as well as undiluted) mixed with 
undiluted vector (1:17) and incubated at up to 6 hours.
Ferahemeb −0.086 +++ 1:31, 1:11, 1:6 saline dilutions of Feraheme (and undiluted) mixed with 
undiluted vector (1:17) and incubated at up to 6 hours.
aControl incubations of 1:31 and 2:31 saline-diluted ProHance with Toca 511 not infused through a needle resulted in transduction titers with difference in logs from 
the control of −0.040 and −0.014, respectively. bTransduction titer difference data shown from the undiluted ProHance or Feraheme with Toca 511 1:17 mixture 
upon 6-hour incubation. Results from lower concentrations of ProHance as well as all earlier time points showed no significant changes in titers (data not shown). 
CTRL, control.
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devices except the Neurocut titanium biopsy needle, which showed 
a variable time dependent drop in apparent vector titer.
Toca 511 is compatible with the surgical hemostatic material 
SURGICEL but SURGIFOAM causes deleterious changes in pH
Toca 511 was assessed for stability in the presence of SURGICEL ster-
ile absorbable hemostat, SURGIFOAM absorbable gelatin sponge, 
and Gelfoam (absorbable gelatin sponge). These hemostatic agents 
are often used in a surgical setting to control bleeding after tumor 
resection. The hemostatic agents were cut into approx. 0.5 × 0.5 cm 
squares (1–10 squares of SURGICEL or SURGIFOAM, and up to eight 
squares for Gelfoam) and incubated for 2 hours at ambient tem-
perature with 1 ml of a 1:200 (1:50 for the Gelfoam samples) media 
dilution of Toca 511. SURGICEL and SURGIFOAM assessments were 
made by either adding the cut squares directly to the diluted vector 
or presoaking the squares in sterile saline prior to transferring to the 
diluted vector (data for the saline-soaked samples not shown; com-
patibility results were equivalent to the directly added samples). 
During the incubation with SURGICEL, a color change in the dilu-
tion media (from the phenol red, see Figure 3a) as a function of the 
number of squares present during the incubation, indicative of a 
lower pH. SURGIFOAM did not significantly change the media color. 
The extent of the pH change was confirmed by direct measurement 
(Figure 3b). The pH dropped from 7.78 for the media-diluted vector 
alone to 3.17 when incubated with SURGICEL (10 squares), while it 
only dropped to 7.19 when incubated with SURGIFOAM (10 squares) 
and 5.81 while incubated with Gelfoam (8 squares). For SURGICEL, 
titer determination of the samples revealed a sharp drop in trans-
duction titers that was dependent on the total surface area of the 
SURGICEL squares incubated with the vector (Figure 3c; Table  3). 
Incubations with Gelfoam indicate compatibility with the smallest 
surface area exposure (1 square), but decreasing compatibility as a 
function of surface area of the agent. By contrast, incubations with 
the SURGIFOAM had a minimum impact on pH and measured no 
impact on transduction titers indicating good compatibility.
Toca 511 is compatible with cerebrospinal fluid, blood, serum, and 
plasma
We also assessed the impact on Toca 511 vector activity of direct 
contact with cerebrospinal fluid (CSF), serum, and heparin or ethyl-
enediaminetetraacetic acid (EDTA) plasma). A 1:10 dilution of Toca 
511 was incubated with increasing amounts of CSF (4.8–90.5% by 
volume in formulation buffer for a total final dilution of Toca 511 of 
1:105) for 2 hours at ambient temperature. Table 4 shows that no 
significant losses of transduction titers were observed, demonstrat-
ing good biocompatibility in the presence of CSF. For blood com-
patibility testing, Toca 511 was spiked (100 µl into 900 µl) into fresh 
drawn whole blood from a healthy adult volunteer and serum or 
plasma with EDTA or sodium heparin prepared. All samples were 
centrifuged upon completion of the incubation period (20 seconds) 
to remove any clotted material and supernatants analyzed for trans-
duction titers. Table 4 shows none of these matrices caused a signifi-
cant loss in titer, indicating that clotted blood and blood-containing 
EDTA or heparin anticoagulants are compatible with Toca 511 under 
these conditions.
Ethanol inactivates Toca 11 more readily than DMSO
Solvents (ethanol and DMSO) common in the dissolution of small 
molecule drugs for in vitro and in vivo studies were investigated 
for effect on Toca 511 titers. The stability of Toca 511 over time 
with increasing concentrations of these solvents (0.5–50% by 
volume individually and 1–12.5% in equal proportion) was mea-
sured. These data showed that Toca 511 was not inactivated by 
up to 12.5% ethanol and up to 25% DMSO at time zero (i.e., mea-
sured immediately after mixing) The combination of DMSO and 
ethanol at 12.5% each, was also not immediately inactivating 
(Table 4). However, after 4 hours at ambient temperature, etha-
nol concentrations above 5% and DMSO/ethanol mixes above 
5% each reduced the vector titer by up to 25%. DMSO alone (up 
to 12.5%) did not decrease vector titers over 4 hours at ambient 
temperature.
Table 2 Compatibility of Toca 511 with surgical delivery devices
Device Difference from 
CTRL (log)a
Compatibility Notes on methodology (all incubations and dwell 
times occur at ambient temperatures)
Steel Biopsy Needle (Ad-Tech) −0.010 +++ Slow manual infusion of undiluted Toca 511 
collected at intervals over 4 hours.
Neurocut Titanium Biopsy Needle (in vivo): study A 0.596 NC Slow manual infusion of undiluted Toca 511 
collected at intervals over 4 hours.
Neurocut Titanium Biopsy Needle (in vivo): study B 0.189 ++ Slow manual infusion of undiluted Toca 511 
collected at intervals over 2 hours.
Steel Coudé Blunt Nerve Block Needle (Epimed) −0.086 +++ Slow manual infusion of undiluted Toca 511 
collected at intervals over 2 hours.
Rickham Catheter/Reservoir  
(Vygon S.A., polysulfone)
−0.022 +++ Slow manual infusion of 1:50 (formulation buffer) 
Toca 511 collected at intervals over 2 hours.
MANTIS (Medtronic) −0.110 +++ Undiluted Toca 511 infused at a rate of 200 µl/h 
over 6 hours via MiniMed Paradigm pump.
MRI-Compatible SmartFlow Cannula  
(MRI Interventions, silica inner lumen)
0.051 +++ Undiluted Toca 511 infused at a rate of 10 µl/min. 
over 4 hours via laboratory syringe pump.
MANTIS, Medtronic Acute Neurological Therapy Infusion System; NC, not compatible.
aDifference shown is based on log of transduction titers of samples at the final collected time point vs. the analogous control.
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Temperature-dependent gel, Lutrol F 127, does not inactivate Toca 
511
Lutrol F 127 is a candidate delivery matrix for Toca 511 as it retains 
low viscosity at 0–4 °C and becomes highly viscous at temperatures 
between ambient and 37 °C. The vector-loaded gel may slow vector 
diffusion from the delivery area and, therefore, has the potential to 
enhance local delivery through slow release of the vector. Toca 511 
was mixed 1:40 with a 20% aqueous Lutrol F 127 solution (19.5% 
final) and allowed to sit on ice along with control vector similarly 
diluted in phosphate-buffered saline for 60 minutes prior to trans-
duction. In this assessment, Toca 511 retained transduction titer 
equivalent to controls, indicating the compatibility of Toca 511 with 
this potential adjuvant (Table 4).
DISCUSSION
Despite considerable activity in the use of replicating viruses for 
treating cancer16 and brain cancer in particular,9 there have been few 
reports of systematic investigations of biocompatibility of agents 
used in this context. In this report, we describe the methods and 
results of biocompatibility studies of Toca 511, a RRV under investi-
gation for the treatment of recurrent high grade glioma (HGG) in two 
protocols: (i) by transcranial injection into the tumor (NCT01156584) 
and (ii) by the injection of the resection cavity for those patients who 
chose a resection upon recurrence (NCT01470794). Stereotactic, 
transcranial injection is guided by real-time MRI visualization to 
accurately deliver vector to the tumor. Prior to initiating these clini-
cal trials, compatibility testing needed to be performed to assess any 
negative impact on Toca 511 infectivity as a result of direct contact 
with different types of delivery devices, MRI contrast agents, and 
body fluids. Several general investigations of the stability of ampho-
tropic retroviruses11–13 indicate cholesterol levels10,17 as well as the 
stability of the envelope protein complex18 may contribute to sensi-
tivities to temperature, pH, and buffer conditions.
Toca 511 is generally stable under conditions commonly encoun-
tered during usage and/or in samples obtained for clinical labora-
tory tests. Exceptions include SURGIFOAM and titanium needles. In 
addition, we demonstrated the use of a sterile needless vial adaptor 
that will allow the removal of the vector without having to directly 
contact the vial and break sterility. Toca 511 is not affected by 
ProHance, a commonly used MRI contrast agent, which allows real 
time or near real time visualization of the vector fluid after injections 
into patients’ brains.
Figure 3 Compatibility assessments of Toca 511 with hemostatic agents. (a) pH indicator color changes from a 1 ml (1:200) dilution of Toca 511 with 1, 2, 
4, 6, 8, or 10 squares (0.5 × 0.5 cm/sq) of SURGICEL or SURGIFOAM absorbable hemostatic agent. (b) pH measurements (Orion ROSS Micro pH Electrode 
(P/N 8220BNWP) of controls and the 2 hours, ambient temperature incubations (average of three determinations shown). (c) Transduction titer results 
from Toca 511/hemostat incubations. Twenty microliters of the incubation or the no-hemostat control was transferred to seeded host PC-3 cells for 
determination of proviral copy number after the initial round of infection (see materials and methods). Compatibility determinations (Table 3) were 
determined comparing incubation test articles to controls. SURGICEL became nonmeasurable for incubations greater than two squares. Gelfoam was 
tested for compatibility by combining saline-diluted (1:50) Toca 511 to 1, 2, 4, or 8 (0.5 × 0.5 cm) squares (6 and 10 square samples were not measured 
as with the other hemostatic agents) and incubated at ambient temperature for 2 hours.
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In addition, Toca 511 is stable under ambient conditions for at 
least 6 hours after thawing. This time should be sufficient to retrieve 
Toca 511 from the pharmacy where it is stored frozen, transfer it to 
the operating theater, and administer it either by transcranial injec-
tion or into the walls of the resection cavity.
Multiple delivery devices capable of varying the infusion rate of 
delivery are available on the market. We found that with one excep-
tion all delivery devices tested were biocompatible with Toca 511. A 
titanium-based biopsy needle demonstrated a negative effect when in 
contact with the vector for longer dwell times (4 hours). Biocompatible 
devices include steel biopsy needles (BrainLAB, Ad-Tech, Racine, WI); 
Blunt Nerve Block needle (Epimed, Johnstown, NY); Rickham Catheter/
Reservoir (Vygon S.A; Vygon, Lansdale, PA.), MANTIS investigational 
device; Medtronic, Minneapolis, MN), and MRI-Compatible SmartFlow 
Cannula (MRI Interventions, Memphis, TN).
One of the more important finding of this study is the incompat-
ibility of Toca 511 with the hemostatic agent SURGICEL (an absorb-
able cloth-like material made from oxidized cellulose) commonly 
used to control bleeding during and after neurosurgical  procedures. 
The study demonstrated that this agent lowers the pH of the test 
environment. The pH drop is believed to have had a negative effect 
on the infectivity of Toca 511. Based on these findings, SURGICEL 
is excluded from use in the current clinical trials of Toca 511. 
SURGIFOAM (an absorbable sponge-like agent made of gelatin), 
and to a lesser extent Gelfoam, are recommended as alternative 
hemostatic agents to control bleeding where necessary.
The current study should alleviate the concern that body fluids 
could negatively impact the infectivity of Toca 511. The Toca 511 
vector is produced from a human cell line. Previous work dem-
onstrated that retroviral vectors produced from human cell lines 
are relatively resistant to inactivation by human blood, includ-
ing complement-mediated inactivation.24 This report was able 
to support this finding as human whole blood (pre- or postclot) 
did not appear to have any impact on the infectivity of Toca 511. 
Exposure to CSF also showed complete compatibility with Toca 
511 for at least 2 hours.
In summary, formulations of Toca 511 appear to have good sta-
bility characteristics capable of withstanding most operating room 
situations tested here, including 6 hours stability at room tempera-
ture after thawing from freezing at ≤ −65 °C. A notably incompat-
ible product was SURGICEL, a hemostatic device that reduces pH 
upon contact with aqueous liquids. Otherwise Toca 511 was able 
to withstand exposure to a variety of physical and chemical agents 
used in the required neurosurgical procedures. Nevertheless, it will 
be valuable to continue testing any new excipients or devices when 
their use with Toca 511 is considered.
In conclusion, our data show that it is important to conduct stud-
ies, such as these with novel biological treatment agents, as the 
risk of inactivation is difficult to predict without experimental veri-
fication. This strategy eliminates possible sources of uncertainty in 
interpreting clinical trial results, and maintains the expected risk/
benefit ratio for clinical trial subjects.
Table 3 Compatibility of Toca 511 with hemostatic agents
Hemostatic agent Difference from CTRL (log) (surface 
area of hemostatic agent tested)
Compatibility Notes on methodology (all incubations and dwell times 
occur at ambient temperatures)
SURGICEL absorbable 
(oxidized cellulose-based 
cloth-like hemostat)
−0.107 (0.25 cm2) +++ 1 ml of a 1:200 dilution of Toca 511 was incubated with 
indicated amounts of SURGICEL for 2 hours prior to 
determination of transduction titer.
0.263 (0.50 cm2) +
n/d (1.00 cm2) NC
n/d (1.50 cm2) NC
n/d (2.00 cm2) NC
n/d (2.50 cm2) NC
SURGIFOAM absorbable 
(gelatin-based sponge-like 
hemostat)
−0.145 (0.25 cm2) +++ 1 ml of a 1:200 dilution of Toca 511 was incubated with 
indicated amounts of SURGIFOAM for 2 hours prior to 
determination of transduction titer.
−0.056 (0.50 cm2) +++
−0.066 (1.00 cm2) +++
−0.095 (1.50 cm2) +++
−0.107 (2.00 cm2) +++
−0.059 (2.50 cm2) +++
Gelfoam Absorbable Gelatin 
Sponge, USP
0.113 (0.25 cm2) ++ 1 ml of 1:50 saline-diluted Toca 511 was incubated with 
indicated amounts of Gelfoam for 2 hours prior to the 
determination of transduction titer.
0.150 (0.50 cm2) ++
0.284 (1.00 cm2) +
0.532 (2.00 cm2) NC
NC, not compatible; n/d, samples whose infectivity and proviral copy number are not detectible by the transduction titer assay method (see Materials and 
Methods).
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MATeRIAlS AND MeTHODS
Needles and delivery devices
The following devices were tested: Stainless steel disposable biopsy needle 
(BrainLAB AG, Feldkirchen, Germany); stainless steel disposable biopsy nee-
dle (Ad-Tech; P/N DBN-08-19X); Neurocut titanium biopsy needle (In vivo, 
Hennigsdorf, Germany; Ref # 2014-03); fused silica CED catheter (Polymicro 
Technologies; P/N TSP 320450) coupled to PFA Teflon tubing (0.02′′ ID × 
1/16′′ OD; Upchurch Scientific, IDEX, Oak Harbor, WA; P/N 1622); Coudé blunt 
nerve block needle (Epimed; Ref # 117–2230); 1/2CC U-100 Insulin syringe, 
1-,  3-, 5-, and 10-ml BD Luer-Lok syringes and 21G (Ref # 305167) needle 
(BD, Franklin Lakes, NJ); Rickham Catheter/Reservoir (Vygon S.A., PC01 15 cm 
ventricular catheter; Vygon S.A., VR05 polysulfone Rickham Reservoir); MRI 
Interventions Smartflow neuro ventricular cannula (MRI Interventions; Ref 
# NGS-NC-02; 10 f. by 0.008′′ internal diameter); MANTIS, an investigational 
intracranial catheter and extension set, an investigational cranial anchor, an 
accessory kit, and an external MiniMed Paradigm pump adapted for this 
investigational use (Ref # 8764, 8763, 8765 and MMT-715NALN, respectively; 
Medtronic).
Hemostatic materials
The following materials were tested: SURGICEL sterile absorbable hemo-
stat (oxidized cellulose-based cloth-like hemostat, Johnson and Johnson, 
P/N 1952); SURGIFOAM (absorbable gelatin-based sponge-like hemostat; 
Johnson and Johnson; P/N 1972); Gelfoam (absorbable gelatin sponge, USP; 
Pfizer Pharmaceutical).
Solvents, adjuvants, biofluids, and MRI contrast reagents
The following liquid agents were tested: saline (0.9% sodium chloride, injec-
tion, USP, NDC 0409-7983-02; Hospira, Lake Forest, IL); dimethyl sulfoxide 
(Calbiochem, Merck Millipore, Darmstadt, Germany); ethanol (Absolute for 
Molecular Biology, Sigma-Aldrich, St Louis, MO); ProHance (Gadoteridol 
Injection, 279.3 mg/ml; Bracco Diagnostics, Monroe Township, NJ); Feraheme 
(Ferumoxytol) injection (AMAG Pharmaceuticals, Waltham, MA); Lutrol F 127 
(BASF, Ludwigshafen, Germany, article 51632903); CSF (BioReclamation, 
Westbury, NY; P/N HMCSF, lot # BRH45611); peripheral blood from a normal, 
healthy individual drawn into glass serum, EDTA, or heparin (Vacutainer, Ref. 
366430, 366643 and 367871, respectively; BD) blood tubes.
Table 4 Compatibility of Toca 511 with biofluids, solvents, and adjuvants
Fluid agent Difference from 
CTRL (log)
Compatibility Notes on methodology (all incubations and dwell times occur at ambient temperatures)
Biofluids
   Cerebrospinal fluid 
(CSF)
−0.061 +++ CSF was incubated from 4.8–90.5% volumetrically with a 1:10 dilution (in formulation 
buffer) of Toca 511 and incubated for 2 hours prior to titer measurement.
Human whole blood
  (serum preclot) −0.009 +++ Blood collected to serum tubes was divided to preclot and postclot. Toca 511 was 
added at a ratio of 1:10 and mixed before clotting with “preclot” and added and mixed 
after clotting for 20 minutes for “postclot.” Toca 511 was added at a 1:10 ratio, mixed, 
and incubated for 20 minutes in blood with EDTA or heparin. All samples were spun 
and supernatants further diluted 1:10 in culture media prior to transduction.
  (serum postclot) −0.084 +++
  (EDTA plasma) −0.057 +++
  (heparin plasma) 0.002 +++
Solvents
  Ethanol (up to 5%) 0.070 +++ Toca 511 was diluted 1:20 in media prior to mixing 1:1 with solvents and diluted 
solvents (1:40 final for vector). Percentage shown is the % solvent (% each solvent for 
the 1:1 combination). Data shown represents the results of the 4 hours incubation; 
To determine the impact of limited exposure, time points of 30, 60, and 120 minutes 
were also collected and analyzed. For EtOH samples, incubations at 12.5% were 
fully compatible (+++) until 2 hours. For DMSO samples, incubations at 25% were 
compatible (+++) until 2 hours as well. For the EtOH:DMSO mixture, 12.5% was 
compatible (+++) at 30 minutes and dropped significantly (+) by 1 hour.
    (12.5%) 0.248 ++
    (≥25%) n/d NC
  DMSO (up to 12.5%) −0.052 +++
    (25%) 0.137 ++
    (50%) n/d NC
   1:1 EtOH/DMSO (1%) 0.055 +++
    (2%) 0.198 ++
    (5%) 0.292 +
    (12.5%) 0.898 NC
Adjuvant
   20% Lutrol F 127 
(aqueous)
0.060 +++ Toca 511 was mixed 1:40 with 20% Lutrol and incubated 1 hour on ice to maintain low 
viscosity (at ambient to 37 °C, aqueous Lutrol resembles a firm colloid suspension) 
prior to host cell transduction.
DMSO, dimethyl sulfoxide; EDTA, ethylenediaminetetraacetic acid; EtOH, ethanol.
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To evaluate ProHance, 50 µl of a 1 mmol/l ProHance solution in saline was 
added to 800 µl of Toca 511 (1:17) for a final concentration of 0.53 mg/ml 
gadoteridol (referred to as 1:31). Additional studies with higher concentra-
tions of ProHance, 1.06, 1.49, 2.74, and 16.43 mg/ml final gadoteridol (2:31, 
1:11, 1:6, and undiluted dilutions, respectively) were conducted. Feraheme 
compatibility with Toca 511 was investigated in a similar manner to the 
ProHance dilution paradigm. The same 1:31, 1:11, and 1:6, straight dilutions 
as for ProHance were prepared in saline and combined with Toca 511 in a 
1:17 ratio as described in the ProHance method above.
Toca 511
Toca 511 is a murine RRV with an amphotropic envelope and a modi-
fied yeast CD transgene expressed from an internal ribosome entry signal 
(IRES). Toca 511 is categorized as a Risk Group 2 (RG2) virus described in 
the NIH Guidelines for Research Involving Recombinant DNA Molecules. 
Construction, modifications, and infectious vector production has been pre-
viously described.1,3
Toca 511 transduction titer
Compatibility assessments were based on transduction titer (TU/ml) deter-
minations of vector preparations after exposure to an agent or device for 
various times or under a variety of conditions compared to appropriate 
controls. Transduction titers were determined by measuring the integrated 
copy number of the Toca 511 provirus after an initial round of infection of 
PC-3 cells (human prostate carcinoma, ATCC no. CRL-1435). Host PC-3 cells 
were cultured at 37 °C and 5% CO2 in complete DMEM supplemented 10% 
with gamma-irradiated, heat-inactivated FBS (Hyclone, Logan, UT), 2 mmol/l 
Glutamax (Invitrogen, Life Technologies, Carlsbad, CA), and 10 µmol/l 
sodium pyruvate (Hyclone) (also known as culture media). Twelve to eigh-
teen hours prior to transduction, host cells were harvested, counted, and 
seeded at 2 × 105 cells/well in 12-well plates. On the day of transduction, 
compatibility assessment samples, reference standards, and controls were 
set up ahead of time to complete any dwell-time and/or incubation such 
that all transductions occurred together. Typically, 20 µl of a 1:10–1:200 
dilution (in culture media to be within linear range of transduction of the 
assay) of controls and test articles were used to transduce host cell wells (in 
triplicate) in the presence of 4 µg/ml hexadimethrine bromide (polybrene) 
(Sigma-Aldrich; 1 mg/ml stock in phosphate-buffered saline sterile filtered). 
Cells were returned to the incubator for 20–28 hours followed by addition 
of Azido-3′-deoxythymidine (AZT) (Sigma-Aldrich; 10 mmol/l stock in phos-
phate-buffered saline sterile filtered) to 40 µmol/l to arrest subsequent viral 
replication. On an additional 24 hours of incubation (44–52 hours posttrans-
duction), cells were harvested to purify genomic DNA (gDNA) by phosphate-
buffered saline rinse and trypsinization (Trypzean; Sigma-Aldrich). DNA was 
purified using a Promega Maxwell 16 automated purification instrument 
using Maxwell 16 Tissue DNA Purification Kits (Promega, Madison, WI) 
(AS1030). Once purified, gDNA concentrations were measured in triplicate 
and averaged using a Nanodrop ND-8000 (Thermo Scientific, Waltham, MA). 
Absolute quantitative PCR (qPCR) was performed in triplicate on each prepa-
ration using primers and probes (Integrated DNA Technologies; forward: 5′-
AGC CCA CAA CCC CTC ACT C-3′; reverse: 5′-TCT CCC GAT CCC GGA CGA-3′; 
probe: 5′-(FAM)-CCC CAA ATG AAA GAC CCC CGC TGA CG-(BHQ)-3′) to span 
the U3 to Psi region of the MLV backbone producing a 192-bp  amplicon. 
QPCR was performed on a Bio-Rad CFX96 Real Time System (Bio-Rad 
Laboratories, Hercules, CA) using the following parameters: 95 °C for 5 min-
utes followed by 38 cycles of 95 °C for 15 seconds, 60 °C for 30 seconds, and 
channel 1 (FAM) fluorophore measurement. The proviral copy number was 
determined using an intraplate 7-log serial dilution plasmid standard mea-
sured in triplicate. Proviral copy numbers were used to determine the initial 
number of transduction events during transduction.
Statistics and compatibility determinations
Within individual assays for the compatibility assessments, transduction titers 
were determined from averaging a minimum of three transduction events 
from which the proviral copy number measurements were made from trip-
licate qPCR reactions within replicate transduction wells (thus transduction 
titer determinations are from a minimum of nine averaged qPCR proviral copy 
number determinations from the three replicate transductions) and converted 
to transduction titer as described above. Intraassay precision determinations 
using a Toca 511 reference vector indicate an ~20% CV corresponding to a 
0.10 log difference of the transduction titers. Interassay precision measure-
ments over >20 assays for the same reference vector indicated an ~30% CV.
Because the assay utilized is a biological assay and subject to some assay 
variability, compatibility differences were compared in increments of 0.25 
log differences of average replicate measurements to identify changes in 
titer between the various conditions and time points. To assess the compat-
ibility of Toca 511 under the conditions described in this report, we defined 
criteria based on the changes observed in transduction titer in increments 
of 0–0.1 (+++), 0.1–0.25 (++), 0.25–0.5 (+), and >0.5 (not compatible) log dif-
ferences from controls.
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